These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24069472)

  • 1. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia.
    Tornheim JA; Lozano Beltran DF; Gilman RH; Castellon M; Solano Mercado MA; Sullca W; Torrico F; Bern C
    PLoS Negl Trop Dis; 2013; 7(9):e2407. PubMed ID: 24069472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.
    Torrico F; Gascón J; Barreira F; Blum B; Almeida IC; Alonso-Vega C; Barboza T; Bilbe G; Correia E; Garcia W; Ortiz L; Parrado R; Ramirez JC; Ribeiro I; Strub-Wourgaft N; Vaillant M; Sosa-Estani S;
    Lancet Infect Dis; 2021 Aug; 21(8):1129-1140. PubMed ID: 33836161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.
    Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA
    Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
    Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Silvestre de Sousa A; Sangenis LHC; Brasil PEAAD; Mejía RA; Fux CP; Cubides JC; Saraiva RM; Brum-Soares LM
    J Antimicrob Chemother; 2017 Sep; 72(9):2596-2601. PubMed ID: 28645201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment.
    Aldasoro E; Posada E; Requena-Méndez A; Calvo-Cano A; Serret N; Casellas A; Sanz S; Soy D; Pinazo MJ; Gascon J
    J Antimicrob Chemother; 2018 Apr; 73(4):1060-1067. PubMed ID: 29351667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance of benznidazole in a United States Chagas Disease clinic.
    Miller DA; Hernandez S; Rodriguez De Armas L; Eells SJ; Traina MM; Miller LG; Meymandi SK
    Clin Infect Dis; 2015 Apr; 60(8):1237-40. PubMed ID: 25601454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of benznidazole use in the treatment of chronic Chagas' disease.
    Hasslocher-Moreno AM; do Brasil PE; de Sousa AS; Xavier SS; Chambela MC; Sperandio da Silva GM
    J Antimicrob Chemother; 2012 May; 67(5):1261-6. PubMed ID: 22331592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil.
    Gontijo MKCL; Arruda HMBDS; Noronha EF; Toledo MI
    Rev Soc Bras Med Trop; 2020; 53():e20190150. PubMed ID: 31994658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of compliance to congenital Chagas disease treatment: results of a randomised trial in Bolivia.
    Chippaux JP; Salas-Clavijo AN; Postigo JR; Schneider D; Santalla JA; Brutus L
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):1-7. PubMed ID: 23296694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis.
    Pérez-Molina JA; Pérez-Ayala A; Moreno S; Fernández-González MC; Zamora J; López-Velez R
    J Antimicrob Chemother; 2009 Dec; 64(6):1139-47. PubMed ID: 19819909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain.
    Ramos JM; Torrús D; Amador C; Jover F; Pérez-Chacón F; Ponce Y; Arjona FJ; Caro E; Martínez-Peinado C; Gallegos I; Cuadrado JM; Tello A; Gutiérrez F
    Pathog Glob Health; 2012 Oct; 106(6):340-5. PubMed ID: 23182138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail.
    Crespillo-Andújar C; Chamorro-Tojeiro S; Norman F; Monge-Maillo B; López-Vélez R; Pérez-Molina JA
    Clin Microbiol Infect; 2018 Dec; 24(12):1344.e1-1344.e4. PubMed ID: 29906591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions.
    Correia JPR; Costa ACD; Rocha EA; Quidute ARP; Cândido DDS; Ponciano ÂMS; Fonteles MMF; Oliveira MF
    Rev Soc Bras Med Trop; 2017; 50(3):334-340. PubMed ID: 28700051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country.
    Carrilero B; Murcia L; Martínez-Lage L; Segovia M
    Rev Esp Quimioter; 2011 Sep; 24(3):123-6. PubMed ID: 21947093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
    Sperandio da Silva GM; Mediano MF; Alvarenga Americano do Brasil PE; da Costa Chambela M; da Silva JA; de Sousa AS; Xavier SS; Rodrigues da Costa A; Magalhães Saraiva R; Hasslocher-Moreno AM
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6371-7. PubMed ID: 25114135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance of benznidazole in treatment of Chagas' disease in adults.
    Pinazo MJ; Muñoz J; Posada E; López-Chejade P; Gállego M; Ayala E; del Cacho E; Soy D; Gascon J
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4896-9. PubMed ID: 20823286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.